文献速递药物相互作用药物不良反应与药物警戒

伊曲康唑对多达维普隆药代动力学影响的I期随机交叉试验

A phase 1, randomized, crossover trial to assess the effect of itraconazole on the pharmacokinetics of dordaviprone in healthy adults.
PubMed 文献 · Br J Clin Pharmacol · 2025-04-27

该研究通过体外实验和18名健康受试者的I期随机交叉试验,评估强CYP3A4抑制剂伊曲康唑对多达维普隆药代动力学的影响。结果显示,联用伊曲康唑后多达维普隆的Cmax和AUC分别增加1.9倍和4.5倍,证实CYP3A4是其 major 清除途径,提示与强CYP3A4抑制剂合用时需调整剂量。

要点

  • 伊曲康唑使多达维普隆Cmax增加1.9倍、AUC增加4.5倍。
  • CYP3A4是多达维普隆氧化的主要代谢酶。
  • 与强CYP3A4抑制剂联用时,625 mg剂量需调整。

核心结论

  • 多达维普隆与伊曲康唑联用显著增加其暴露,证实CYP3A4是主要清除途径。

研究设计与样本

  • 体外采用人肝微粒体和重组人CYP酶试验评估代谢。
  • 临床为18名健康男女性受试者参与的3周期开放标签随机交叉生物等效性和药物相互作用评价的一部分。
  • 多达维普隆及代谢物ONC207血浆浓度用经验证的LC-MS/MS法测定。

主要发现

  • 体外试验提示CYP3A4是参与多达维普隆氧化的主要CYP酶。
  • 与单用多达维普隆相比,联用伊曲康唑后多达维普隆Cmax和AUC分别增加1.9倍和4.5倍。
  • 单用多达维普隆后1名(5.6%)受试者报告治疗中出现的不良事件,联用伊曲康唑后4名(22.2%)报告。

关键数值与推荐

  • 单次125 mg多达维普隆联用伊曲康唑总体耐受良好。
  • 接受625 mg多达维普隆的患者联用强CYP3A4抑制剂时需调整剂量。

临床怎么用

  • 临床使用多达维普隆时应评估联用强CYP3A4抑制剂的风险。
  • 对使用625 mg多达维普隆的患者,联用强CYP3A4抑制剂需调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Dordaviprone (ONC201) is a novel, small molecule with antitumor efficacy in gliomas. The aim of this work was to evaluate the pharmacokinetics and safety of dordaviprone when given alone and when coadministered with a strong cytochrome P450 (CYP)3A4 inhibitor, itraconazole. METHODS: In vitro human liver microsomes and recombinant human CYP enzyme assays were used to assess CYP-mediated metabolism of dordaviprone. The clinical study was conducted in 18 healthy male and female participants as part of a larger 3 period open-label, randomized, crossover bioequivalence and drug-drug interaction evaluation. Dordaviprone and metabolite ONC207 plasma concentrations were determined by validated liquid chromatography-tandem mass spectrometry methods. RESULTS: In vitro assessments of CYP-mediated dordaviprone metabolism indicated that CYP3A4 was the major CYP involved in the oxidation of dordaviprone. Accordingly, concomitant administration of dordaviprone with itraconazole significantly increased dordaviprone plasma maximum plasma concentration and area under the plasma concentration-time curve by 1.9 and 4.5-fold, respectively, compared to dordaviprone alone. Treatment-emergent adverse events were reported by 1 (5.6%) participant after receiving dordaviprone alone, and by 4 (22.2%) participants after receiving dordaviprone with itraconazole. CONCLUSION: Concomitant administration of dordaviprone with itraconazole significantly increased dordaviprone exposure confirming CYP3A4 is a major clearance pathway for dordaviprone. While dordaviprone was generally well tolerated when administered as a single 125-mg dose with concomitant itraconazole, dose adjustment in patients receiving 625 mg dordaviprone with strong CYP3A4 inhibitors is warranted.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Faison SL, Batonga J, Arumugham T, et al. A phase 1, randomized, crossover trial to assess the effect of itraconazole on the pharmacokinetics of dordaviprone in healthy adults. Br J Clin Pharmacol. 2025. PMID: 40289283. doi:10.1002/bcp.70080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。